American Skin Association Announces 2021 Research Grants for Skin Cancer and Diseases
News provided by
Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ American Skin Association has announced the awarding of two coveted research grants under the
ASA Milstein Research Scholar Awards program
.
ASA Milstein Research Scholar Award for Melanoma/Non-Melanoma Skin Cancer and
Ester Del Duca, MD of the Icahn School of Medicine at Mount Sinai received the
ASA Milstein Research Scholar Award in Atopic Dermatitis.
This year of grants includes the
ASA Daneen & Charles Stiefel Investigative Scientist Award in Melanoma Research awarded to
Elena Piskonouva, PhD of Weill Cornell Medicine. The Stiefel Family, longtime supporters of ASA, generously contributed $300,000 to support grants for melanoma research. The purpose of this funding is to identify and support emerging leaders in dermatology focused on melanoma research. Specifically catering to mid-ca
SciBase receives important European MDR certification
STOCKHOLM, May 10, 2021 /PRNewswire/
SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has been granted certification under the new Medical Device Regulation (MDR).
MDR is a set of mandatory legal requirements central for all companies selling medical devices in the EU. The new regulation comes into effect on May 26
th. SciBase is one of very few medical device manufacturers to have completed the MDR certification, after an intensive two year process. With the MDR Certification in place SciBase can release new products, indications and functionality such as their new Non-melanoma Skin cancer (NMSC) application.
Sun Protection Products Market to Develop New Growth Story | Avon Products, Beiersdorf, Lakme Cosmetics texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Share this article
MUNICH, Dec. 18, 2020 /PRNewswire/
Garching - OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanoma Skin Cancers (NMSCs), announced today that the Rhenium-SCT (Rhenium-188 paste) has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal requirement for supply and marketing of the medical device. This advanced radionuclide therapy technology offers a non-invasive, single session, painless treatment with little to no scarring for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs).
The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia having one of the highest incidence rates in the